bowel disease News
-
Targeting Alternative Opioid Receptor Reduces Drug Side Effects
A new study published in Proceedings of the National Academy of Sciences (PNAS) indicates, “Delta opioid receptors have a built-in mechanism for pain relief and can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inammatory pain with fewer side eects.” Researchers used cells from humans and mice with inammatory bowel ...
-
MedBiome licenses the MetaLab metaproteomic software
MedBiome is pleased to announce that it has licensed the iMetaLab software platform from the University of Ottawa. iMetaLab (imetalab.ca) is a leading bioinformatics software for metaproteomics data analysis. MedBiome uses the iMetaLab software in combination with the RapidAIM assay to identify Precision Microbiome Therapeutics that change the composition of the human microbiome, ...
-
MedBiome licenses the RapidAIM technology from the University of Ottawa
MedBiome is pleased to announce that it has exclusively licensed the RapidAIM technology from the University of Ottawa. RapidAIM is a revolutionary assay to rapidly determine the effects of compounds on individual human living microbiomes. RapidAIM fidelity maintains functional living human microbiomes in 96 well plates and allows the testing of drugs for their effects on the ...
-
BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022
BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, May 11, 2022, at 8:00 ...
By BiomX
-
Symberix Awarded Multiple Grants from National Institutes of Health to Expand Platform of Microbiome-Targeted Drugs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). The two SBIR grants collectively totaling over $1.5 million are awarded by the NIH’s National Center for Advancing Translational ...
-
EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies
EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed. Located at the Strathclyde Business Park in Bellshill, the 20,000-square-foot facility is designed to meet regulatory biologics requirements and product analysis while providing the company end-to-end control of its supply chain, ...
-
Discovery of an anti-inflammatory molecule produced by gut bacteria
Researchers at INRA, INSERM, AP-HP, and UPMC have just discovered a new protein with anti-inflammatory properties, which has been named MAM (microbial anti-inflammatory molecule). It is secreted by the bacterium Faecalibacterium prausnitzii and helps fight intestinal inflammation. This discovery, recently published in the journal Gut, is a major advance in efforts to develop new means of treating ...
-
Atmo Biosciences signs deal with RMIT University to commercialize ingestible gas-sensing capsule for gut health
Atmo Biosciences has signed a licensing deal with RMIT University securing the exclusive worldwide rights to commercialize a ground-breaking ingestible gas-sensing capsule. The Atmo Gas Capsule is set to revolutionize how doctors diagnose and treat common gastrointestinal (GI) disorders by offering a non-invasive, low-cost, and more accurate alternative to current technologies. Patients with ...
-
Iterative Health Redefines Approach to Precision GI Care
Iterative Health, formerly known as Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, has announced a rebrand to reflect the company’s success in utilizing artificial intelligence (AI) to strengthen clinical research and augment clinical decision making within gastroenterology. In this new chapter, Iterative Health will continue to focus on its core ...
-
Symberix Awarded $2 Million from National Institutes of Health to Support Lead Program
Symberix has been awarded the Phase II portion of a Small Business Innovation Research (SBIR) Fast-Track grant from the National Institutes of Health (NIH). The NIH Fast-Track application process expedites award decisions and funding of Phase II applications that have a high potential for commercialization by allowing Phase I and Phase II grant applications to be submitted and reviewed together. ...
-
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
-
Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. The chronic progression of IBD is characterized by periods of symptomatic relapses and symptom-free phases. During relapses, acute inflammation occurs in the bowel of IBD patients, leading to typical symptoms ...
-
Microbiotica Announced as a Finalist in ‘Best Emerging Biotech Company’ Category at OBN Awards 2020
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, been selected as a finalist in the ‘Best Emerging Biotech Company’ category at the OBN Awards 2020. The winners will be announced on Thursday 26th November. Microbiotica has established itself as a leading global player in its field, and most recently it has been recognised for its collaboration with ...
-
Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). The project, to support the ongoing development of Microbiotica’s Live Bacterial Therapeutic (LBT) ...
-
Augurex and Quidel at ACR
Augurex and Quidel are pleased to announce the launch of the JOINTstat® 14-3-3η RUO (research use only) ELISA. This new distribution arrangement will get 14-3-3η testing into the hands of more investigators worldwide, including key opinion leaders and pharmaceutical companies, to advance and grow the body of data for this novel joint damage biomarker in autoimmune diseases. There is ...
-
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. This ODD designation will provide SFA ...
-
Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23
SG-5-00455, the Company’s development candidate for the treatment of IBD, aims to restore mucosal healing by targeting PAI-1/2 Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, today announced that it will host a virtual key opinion leader (KOL) event focused on the role of mucosal healing and ...
-
SetPoint Medical to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum 2019
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that Murthy Simhambhatla, Ph.D., President and Chief Executive Officer, is scheduled to present at the 13th annual Canaccord Genuity Medical Technologies & Diagnostics Forum, being held November 21, 2019 in New York, New York. Event: Canaccord Genuity ...
-
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 20%. This ...
-
Iterative Scopes Partners with One GI to Advance Gastrointestinal Care Through Artificial Intelligence
Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI® will use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you